Jupiter Topco LLC acquired a new stake in Immunome, Inc. (NASDAQ:IMNM – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 45,900 shares of the company’s stock, valued at approximately $973,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Immunome in the second quarter valued at about $186,588,000. T. Rowe Price Investment Management Inc. boosted its position in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. Primecap Management Co. CA purchased a new stake in Immunome during the 2nd quarter valued at about $97,081,000. JPMorgan Chase & Co. grew its stake in Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after acquiring an additional 2,823,144 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Immunome in the 4th quarter valued at about $30,710,000. Institutional investors and hedge funds own 44.58% of the company’s stock.
Immunome Price Performance
Shares of IMNM stock opened at $26.76 on Friday. The company has a market capitalization of $3.04 billion, a PE ratio of -10.58 and a beta of 2.13. The firm’s 50-day moving average is $24.96 and its two-hundred day moving average is $22.57. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $30.06.
Analyst Ratings Changes
A number of research firms have weighed in on IMNM. Wedbush raised their target price on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Barclays assumed coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Truist Financial lifted their price objective on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.64.
Check Out Our Latest Stock Report on Immunome
Insiders Place Their Bets
In other Immunome news, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the completion of the sale, the insider owned 15,805 shares of the company’s stock, valued at $357,509.10. This trade represents a 77.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the transaction, the insider directly owned 50,366 shares in the company, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 682,310 shares of company stock valued at $15,675,566 over the last quarter. 7.21% of the stock is owned by insiders.
About Immunome
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Read More
- Five stocks we like better than Immunome
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report).
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
